Drugs / JBH492
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04240704 | Sep 2020 → Sep 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JBH492 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04240704 ↗ |
| Target | CCR7 | “Anti-CCR7 antibody-drug conjugate (ADC)” NCT04240704 ↗ |